Published in Blood Weekly, July 28th, 1997
The low-molecular weight compound, GT4Y-78BQ-N (GT4Y), is manufactured by Billings Pharmaceutical Co., Chicago, Illinois.
"Our data not only demonstrate the ability to prevent HIV transmission to uninfected cells (or organisms) but also suggest that GT4Y will interfere with the expression of the viral genome in infected cells," concluded Billings researcher John B. Davidson.
Davidson reported the findings in a poster presentation to "New Opportunities for HIV Therapy - From Discovery to Clinical Proof-of-Concept," the 2nd Joint...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.